Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7950262 | 0.97 | USP2 (0.30) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL1192654 | 0.84 | EPHX1 (0.33) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL1463811 | 0.84 | — | — | |
| SCHEMBL19650811 | 0.84 | — | — | |
| Sulfuric Acid SCHEMBL8782471 | 0.83 | USP2 (0.32) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL1443404 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL25212348 | 0.82 | — | — | |
| SCHEMBL4073419 | 0.82 | — | — | |
| SCHEMBL17526051 | 0.80 | — | — | |
| SCHEMBL20279957 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051387-B1 | ANTICANCER PLATINUM (IV) COMPLEXES FOR ORAL ADMINISTRATION | KOREA INST SCI & TECH (KR) | 2003-04-23 | — | — | EP | claimed |
| EP-1051387-A1 | ANTICANCER PLATINUM (IV) COMPLEXES FOR ORAL ADMINISTRATION | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2000-11-15 | — | — | EP | claimed |
| US-5998648-A | PLATINUM CHELATE COMPOUND | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1999-12-07 | — | — | US | claimed |
| WO-1999033782-A1 | ANTICANCER PLATINUM (IV) COMPLEXES FOR ORAL ADMINISTRATION | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1999-07-08 | — | — | WO | claimed |
| US-5665343-A | POLYPHOSPHAZENE | IL-YANG PHARM. CO., LTD (KR) | 1997-09-09 | — | — | US | claimed |
| WO-1997012891-A1 | POLYMERIC PLATINUM COMPLEX, PREPARATION THEREOF, AND ANTICANCER AGENT COMPRISING THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1997-04-10 | — | — | WO | claimed |
| US-5426203-A | Antitumor agents having low toxicity | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1995-06-20 | — | — | US | claimed |
| EP-0232784-B1 | (GEM-HETEROCYCLODIMETHANAMINE-N,N')PLATINUM COMPLEXES | AMERICAN CYANAMID COMPANY (US) | 1992-12-02 | — | — | EP | claimed |
| US-4937358-A | Synthesis of cisplatin analogs | AMERICAN CYANAMID COMPANY (US) | 1990-06-26 | — | — | US | claimed |
| US-20210113712-A1 | METHODS FOR PREPARING CELL TARGETING CONJUGATES AND CONJUGATES OBTAINABLE BY SAID METHODS | LINXIS B V (NL) | 2021-04-22 | — | — | US | disclosed |
| US-20210113712-A1 | METHODS FOR PREPARING CELL TARGETING CONJUGATES AND CONJUGATES OBTAINABLE BY SAID METHODS | LINXIS B V (NL) | 2021-04-22 | — | — | US | disclosed |
| US-20200345862-A1 | TRANSITION METAL-BASED FUNCTIONAL MOIETIES FOR PREPARING CELL TARGETING CONJUGATES | LINXIS B V (NL) | 2020-11-05 | — | — | US | disclosed |
| US-20200345862-A1 | TRANSITION METAL-BASED FUNCTIONAL MOIETIES FOR PREPARING CELL TARGETING CONJUGATES | LINXIS B V (NL) | 2020-11-05 | — | — | US | disclosed |
| EP-2740738-B1 | PLATINUM COMPOUNDS FOR TREATING CELL PROLIFERATIVE DISEASE, PREPARATION METHODS AND USES THEREOF | BEIJING FSWELCOME TECH DEVELOPMENT CO LTD (CN) | 2018-03-28 | — | — | EP | disclosed |
| US-4937358-A | Synthesis of cisplatin analogs | AMERICAN CYANAMID COMPANY (US) | 1990-06-26 | — | — | US | disclosed |
| US-4880790-A | ANTICANCER, ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| US-4870070-A | ANTIEMETICS | AMERICAN CYANAMID COMPANY (US) | 1989-09-26 | — | — | US | disclosed |
| US-4808730-A | Synthesis of cisplatin analogs | AMERICAN CYANAMID COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0296321-A1 | Synthesis of cisplatinum analogs | AMERICAN CYANAMID COMPANY (US) | 1988-12-28 | — | — | EP | disclosed |
| EP-0232784-A2 | (Gem-heterocyclodimethanamine-N,N')platinum complexes | AMERICAN CYANAMID COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210113712-A1 | METHODS FOR PREPARING CELL TARGETING CONJUGATES AND CONJUGATES OBTAINABLE BY SAID METHODS | CD47, EPCAM, CD44 | USP2 1987/4885ALDH1A1 1027/4885LMNA 2122/4885 |
| US-20200345862-A1 | TRANSITION METAL-BASED FUNCTIONAL MOIETIES FOR PREPARING CELL TARGETING CONJUGATES | CD2, CD47, EPCAM | USP2 2765/4885ALDH1A1 919/4885LMNA 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.